CD8A and neoplasm: Both single-dose vaccination and 3-day PBI offered protection in prophylactic tumor challenge experiments but yielded significantly fewer functional cytotoxic CD8+ T cells that exhibited TEM characteristics, which might not provide sufficient protection at peripheral sites where tumors might have originated or recurred after treatment.